Reports Q1 revenue $3.35B, consensus $3.4B. “Labcorp (LH) delivered solid performance in the first quarter of 2025,” said Adam Schechter, chairman and CEO of Labcorp. “While the macroeconomic environment remains dynamic, the critical nature of the work we do in diagnostics and drug development positions us well for success in 2025 and beyond. We continue to progress our pipeline of attractive acquisitions and partnerships and further expand our test menu in four strategic areas, including oncology, women’s health, autoimmune disease and neurology.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Notable companies reporting before tomorrow’s open
- LH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Labcorp Holdings: Buy Rating Maintained Amid Minimal Impact from FDA’s Animal Testing Phase-Out
- Labcorp price target lowered to $274 from $285 at Truist
- Labcorp Holdings Declares Cash Dividend for Shareholders